Katamaran Capital LLP Invests $740,000 in DexCom, Inc. (NASDAQ:DXCM)

Katamaran Capital LLP acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,518 shares of the medical device company's stock, valued at approximately $740,000. DexCom accounts for 0.9% of Katamaran Capital LLP's portfolio, making the stock its 25th biggest position.

Other large investors have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of DexCom during the fourth quarter worth about $385,367,000. Congress Asset Management Co. increased its stake in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Fisher Funds Management LTD bought a new stake in shares of DexCom during the fourth quarter valued at approximately $96,507,000. Two Sigma Advisers LP boosted its position in shares of DexCom by 182.7% during the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company's stock worth $76,659,000 after buying an additional 739,000 shares during the period. Finally, Jennison Associates LLC grew its holdings in DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after buying an additional 710,858 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Mizuho started coverage on shares of DexCom in a report on Thursday. They issued an "outperform" rating and a $85.00 price objective for the company. Finally, Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.00.

Remove Ads

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Up 0.5 %

Shares of NASDAQ:DXCM traded up $0.35 during mid-day trading on Thursday, hitting $67.19. The stock had a trading volume of 5,300,507 shares, compared to its average volume of 4,154,828. The company's 50 day moving average is $77.74 and its 200-day moving average is $76.63. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $141.25. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market cap of $26.34 billion, a PE ratio of 47.18, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.